Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocolWilliam T. Creasman, David S. Miller, Peter A. Argenta et al.|Gynecologic Oncology|2017Cited by 80
Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyDavid R. Spriggs, Mark G. Hanly, Mark F. Brady et al.|Journal of Clinical Oncology|2007Cited by 57
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Andrew B. Nixon, Kirsten B. Burdett et al.|Clinical Cancer Research|2020Cited by 57
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocolWilliam T. Creasman, John F. Boggess, David S. Miller et al.|UNC Libraries|2020Cited by 0